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Multifactorial genesis of enhanced platelet aggregability in patients
with nephrotic syndrome. Platelet aggregation, I.3-thromboglobulin (/3-
TG) and platelet factor 4 (PF 4) release and thromboxane B2 (TxB2)
formation in stimulated platelet-rich plasma were investigated in 13
patients with nephrotic syndrome who had normal serum creatinine
levels (creatinine clearance >70 ml/min/l.73 m2). In contrast to 13 sex-
and age-matched controls, spontaneous platelet aggregation only oc-
curred in patients with nephrotic syndrome with correlation to serum
albumin and plasma fibrinogen levels. The EC50 (estimated concentra-
tion of aggregating agent to cause half maximum velocity of primary
aggregation) for ADP and collagen and threshold concentration of
arachidonic acid (threshold AA) were decreased in patients with
nephrotic syndrome, reflecting a hyperaggregable state. In patients with
nephrotic syndrome EC50 ADP values were significantly correlated to
serum albumin, serum cholesterol and plasma fibrinogen, however,
EC50 collagen or threshold AA did not correlate to these parameters.
Plasma f3-TG levels were increased in patients, whereas plasma PF 4
levels were not significantly changed in patients compared to controls.
In vitro TxB2 formation was elevated in patients only after stimulation
with AA. Nevertheless, after stimulation with collagen and ADP, TxB2
formation was unchanged in patients compared to controls. Platelet
hyperaggregability in nephrotic patients was confirmed in our study.
However, unchanged thromboxane B2 formation after collagen stimu-
lus as well as missing correlations between EC50 collagen or threshold
AA and serum albumin were contradictory to the hypothesis that
enhanced AA availability due to hypoalbuminemia is responsible for
platelet hyperaggregability. Platelet hyperaggregability in terms of EC50
ADP being associated with serum albumin levels as well as to serum
cholesterol and plasma fibrinogen indicate a multifactorial genesis.
Venous and arterial thromboses are common and well known
complications in patients with nephrotic syndrome. Several
investigations have confirmed a state of hypercoagulability due
to increased production of clotting factors, a reduced fibrin-
olytic activity and renal loss of antithrombin III [1—31. In
addition platelet hyperaggregability occurs in nephrotic syn-
drome [4, 5]. Though there are contradictory results [6], some
studies have revealed a negative correlation of serum albumin
with the incidence of thrombosis [7] as well as with platelet
hyperaggregability [7—10].
Platelet hyperaggregability is evident in an enhanced re-
sponse of nephrotic platelets to stimulation with ADP, epineph-
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rine, collagen or arachidonic acid [4, 8, 10—14] as well as in
increased /3-thromboglobulin levels [7, 14, 15].
Platelet hyperaggregability in nephrotic syndrome also coin-
cides with an enhanced thromboxane B2 or malondialdehyde
formation after addition of arachidonic acid [10, 16], collagen
[5] or thrombin [11] to platelet rich plasma. Platelet function
after stimulation with arachidonic acid normalizes after correc-
tion of hypoalbuminemia in vitro or in vivo. Therefore hypoal-
buminemia is thought to modify cyclooxygenase activity by a
reduced binding of arachidonic acid. This would lead to an
enhanced platelet activity and an increased formation of throm-
boxane A2 [10, 16].
To review this pathophysiological concept we studied param-
eters of platelet aggregability and release reaction in patients
with nephrotic syndrome with special regard to thromboxane
B2 formation after stimulation with different agents.
Methods
Patients
Thirteen patients with a proteinuria greater than 3.5 g/24
hr/l.73 m2 body surface area [17] were investigated. Patients
had normal serum creatinine levels; those with a creatinine
clearance below 70 mllminll.73 m2 were excluded as well as
those with systemic disease (such as, diabetes mellitus, lupus
erythematodes) or on corticosteroid therapy. Percutaneous
kidney biopsy specimens were obtained in 11 of 13 patients
(Table 1) and investigated by light microscopy, electron micros-
copy and immunofluorescence staining. The patients gave their
informed consent to participate in the study.
Controls
Thirteen sex- and age-matched volunteers without protein-
una and with normal renal function, who had denied the
ingestion of acetylsalicylic acid or other platelet inhibitors for at
least two weeks before the study were investigated as controls.
Blood collection and plasma preparation
For preparation of platelet rich plasma (PRP) blood was
collected into 3.13% sodiumcitrate (9:1 vol/vol). Blood was
centrifuged 10 minutes at 200 g to obtain PRP and further 10
minutes at 3000 g to obtain platelet poor plasma (PPP). Platelet
number in PRP was adjusted to 2 x 101 'Iliter with autologous
PPP. During the platelet aggregation study PRP was stored in a
plastic syringe to prevent pH instability [18].
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Table 1. Kidney disease, creatinine clearance values (Ccr [mI/mm/I .73 m2]) and serum albumin levels (ALB [g/dl]) in 13 patients with
nephrotic syndrome and corresponding results of ex vivo studies of platelet function
No. Diagnosis Biopsy C, ALB
EC50
ADP Coil
Threshold
AA SpA
1 Proliferative intracapillary yes 143 1.9 0.303 0.712 0.05 18.2
glomerulopathy
2 Focal glomerulosclerosis yes 90 1.9 0,231 0.305 0.05 20.1
3 Minimal change glomerulopathy yes 140 1.7 0.399 0.214 0.10 9.4
4 Minimal proliferative yes 141 2.1 0.345 0.311 0.10 6.3
glomerulopathy
5 Alpha-mercaptopropionyleglyzine- no 70 3.3 0.583 0.272 0.10 0.0
induced nephropathy
6 Membranous glomerulopathy yes 75 1.4 0.337 0.236 0.10 20.0
7 Minimal change glomerulopathy yes 108 2.2 0.240 0.625 0.10 10.9
8 Gold/penicillamine-associated no 80 2.0 0.596 0.395 0.40 10.0
nephropathy
9 Proliferative intracapillary yes 72 2.6 0.575 0.384 0.20 0.0
glomerulopathy
10 Membranous glomerulopathy yes 134 2.7 0.968 0.305 0.20 0.0
11 Membranous glomerulopathy yes 97 2.0 0.407 0.398 0.05 11.0
12 Minimal change glomerulopathy yes 98 2.3 0.515 0.278 0.40 13.0
13 Minimal change glomerulopathy yes 111 1.8 0.427 0.338 0.80 16.5
Platelet functions are: EC50 ADP (MmolIl); EC50 collagen (g/ml); threshold concentration of arachidonic acid, AA (mmol/l); and spontaneous
platelet aggregation, SpA, slope of primary aggregation (%/min).
For measurement of /3-thromboglobulin, blood was collected
into two precooled tubes containing EDTA/theophylline (Am-
ersham Buchler, Braunschweig, FRG), acetylsalicylic acid and
prostaglandin E1 (Sigma Chemicals, FRO) in a final concentra-
tion of 2.5 mmol/liter and 1.0 /Lmol/liter, respectively. After one
hour PPP was prepared by centrifugation at 20 minutes x 3000
g at 0°C.
Platelet aggregation studies
Platelet aggregability was measured by light transmission [19]
in a two-channel-aggregometer (Labor, Ahrensburg, FRG). Ten
doses of ADP ranged in final concentration from 20 ,amol/liter to
0.03 jsmollliter, 8 doses of collagen (Hormon Chemie, MUnchen,
FRO) final concentrations 8.0 tg/ml to 0.06 pg/ml and up to 8
doses of arachidonic acid (final concentrations 1.0 mmollliter to
0.025 mmol/liter) were added in a constant volume of 10 tl to
190 trl PRP.
For ADP and collagen the maximum velocity of primary
aggregation was measured in the steepest initial part of the
curve. According to Thompson and Vickers [201 the sigmoid
relation between log dose of aggregation agent and the primary
aggregating rate was fitted by a computer program using the
sigmoid E-max-model [21]. The resulting EC50 is the estimated
dose of aggregating agent to cause the half maximum response
of aggregating velocity.
Spontaneous platelet aggregation was measured in a stirred
PRP system by adding 10 d of saline 0.9% to 190 jzl of PRP.
The rate of aggregation was expressed as the change in light
transmittance in percent per minute.
Thromboxane B2-RIA
Five minutes after stimulation of PRP with 20 smol/liter
ADP, 8 tLgIm1 collagen or 1 mmollliter arachidonic acid 180 jd
ethanol was added for inhibition of further thromboxane A2
formation. The sample was centrifuged for 15 minutes x 2000 g,
the supernatant was immediately frozen at —20°C. The recov-
ery of 3H-thromboxane B2 after this procedure was 81.3%
5.0%.
Thromboxane B2 (TXB2) was determined by radioimmuno-
assay according to Anhut, Bernauer and Peskar [22]. 3H-TXB2
and purified TXBrstandard were from Dr. C.O. Meese (Mar-
garete-Fischer-Bosch-Institute of Clinical Pharmacology, Stutt-
gart, FRO). The antibody (AFB, Berlin, FRO) had a good
specifity with cross reactions to 6-keto-PGF1a, POD2, POE2,
POE1, PGF1Q and PGF2a below 0.05%.
/3-thromboglobulin and platelet factor 4 levels
Plasma /3-thromboglobulin levels were measured using a
radioimmunoassay kit (Amersham Buchier, Braunschweig,
FRG). Plasma platelet factor 4 levels were also determined by
radioimmunoassay (Abbott Diagnostic Products, Wiesbaden,
FRO).
Statistics
Statistic evaluation of results was done by Student's t-test
and by linear correlation by least squares.
Results
Thirteen patients with nephrotic syndrome were investigated.
The results of renal biopsy and creatinine clearance values of
these patients are shown in Table 1. Compared to 13 sex- and
age-matched controls patients showed a significant thombocy-
tosis, hypoalbuminemia, hypercholesterolemia, reduced anti-
thrombin III levels and increased plasma fibrinogen (Table 2).
Platelet aggregability was investigated by estimated concen-
trations of aggregating agent to cause half maximal velocity of
primary aggregation (EC50) for ADP and collagen, threshold
concentrations of arachidonic acid and the rate of spontaneous
platelet aggregation. The values of these parameters are listed
in Table 1 for each patient. Reduced EC50 values in patients
with nephrotic syndrome indicate an enhanced platelet aggre-
gability in response to ADP (0.455 0.198 ftmollliter vs. 1.12±
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Table 2. Characteristics of 13 patients with nephrotic syndrome
compared to 13 sex- and age-matched healthy volunteers
NephroticN 13 each syndrome Control Significance
Age 46.4 14.8 48.1 14.6 P = 0.772
M:F 8:5 8:5
Creatinine 104.5 27.4 111.5 25.8 P = 0.514
clearance ml!
min/l.73 m2
Creatinine mg/dl 1.06 0.26 0.80 0.15 P 0.0043
Thrombocytes x 283.4 98.7 206.4 25.4 P = 0.012
IO9Iliter
Serum albumin 2.16 0.49 4.39 0.34 P < 10
gidi
AT 111% 81.4 15.4 113.7 11.0 P = 2.4 x 10_6
Cholesterol mg/dl 492.4 134.6 232.2 33.7 P < 10
Fibrinogen mg/dl 729.6 263.1 283.1 95.9 P = 6.4 X 106
Fig. 1. EC50 values (estimated concentrations of aggregating agents to
cause half maximum velocity of primary aggregation) for ADP (umolI
liter) and collagen (ug/ml) and threshold concentration of arachidonic
acid (mmol/liter) in platelet-rich plasma of patients with nephrotic
syndrome (fill) and controls () (mean SD, N = 13 each).
0.395 molIliter, P = 1.4 x iO, mean SD) and collagen
(0.367 0.146 sgfm1 vs. 0.580 0.233 g/m1, P = 0.01, mean
sD; Fig. 1). Threshold concentrations of arachidonic acid
were also reduced in patients with nephrotic syndrome (0.204
0.216 mmoL/l vs. 0.454 0.272 mmollliter, P = 0.016, mean
sD; Fig. 1).
Linear correlations were calculated between EC50 ADP,
EC50 collagen, threshold concentrations of arachidonic acid on
the one hand and serum albumin, cholesterol and plasma
fibrinogen levels on the other hand. The results are shown in
Table 3. Low EC50 ADP values which indicate an enhanced
platelet aggregability were significantly correlated with low
serum albumin levels as well as high serum cholesterol and
plasma fibrinogen levels. EC50 values for collagen and threshold
concentrations of arachidonic acid did not correlate to albumin,
cholesterol or fibrinogen levels. Patients with a serum albumin
below 2.3 g/dl showed a marked spontaneous aggregation which
correlated to serum albumin and plasma fibrinogen. Further-
more, there was a significant intercorrelation between EC50
ADP and spontaneous platelet aggregation (r = —0.702, P =
Table 3. Correlations between parameters of in vitro platelet
aggregation studies and serum albumin, serum cholesterol and plasma
fibrinogen (least squares)
Albumin Cholesterol Fibrinogen
EC50 ADP
r = 0.591 —0.577 —0.593
P = 0.034 0.039 0.033
EC50 collagen
r =
—0.04 —0.21 0.19
Threshold AA
r 0.08 —0.16 —0.20
Spontaneous aggregation
r =
—0.815 0.43 0.683
P = 0.0007 0.14 0.010
Fig. 2. Plasma beta.thromboglobulin levels (ng/ml) and plasma plate-
let factor 4 levels (nglml) detected by radioimmunoassay in patients
with nephrotic syndrome (liii) compared with controls () (mean SD,
N = 13 each).
0.008). Spontaneous platelet aggregation could not be observed
in patients with higher serum albumin levels as well as in
controls.
Moreover, f3-thromboglobulin levels were increased in pa-
tients compared to controls (47.1 20.7 nglml vs. 24.0 8.3
ng/ml, P = 0.0012, mean sD; Fig. 2). PF 4 levels were also
elevated in patients compared with controls, however, the
result was not statistically significant (7.58 4.46 ng/ml vs. 5.46
3.83 rig/mI, P = 0.204, mean SD, Fig. 2).
In vitro thromboxane B2 formation after stimulation with 20
moL/liter ADP, 8 p.g/ml collagen or 1 mmollliter arachidonic
acid was detected by radioimmunoassay. After ADP and colla-
gen stimulation there was no significant difference in thrombox-
ane B2 formation between patients and controls (ADP: 2.84
3.14 ng/ml vs. 3.14 2.61 ng/ml, P = 0.79; collagen: 148.3
57.6 ng/ml vs. 172.5 43.4 ng/ml, P = 0.24, means SD).
Thromboxane B2 formation after arachidonic acid stimulus was
enhanced in patients compared with controls (711.7 268.6
ng/ml vs. 414.5 115.0 nglml, P = 0.001, means SD, Fig. 3).
Discussion
Platelet release products such as f3-thromboglobulin or plate-
let factor 4 has often been studied as an indicator of platelet
hyperaggregability. /3-thromboglobulin levels are known to be
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Fig. 3. Thromboxane B2 levels (ng/ml) in platelet rich plasma 5 miii
after stimulation with ADP (20 p?mol/liter), collagen (8 tg/ml) or
arachidonic acid (1 mmol/liter; mean so, N = 13 each). Symbols are:
(Ill) nephrolic; () controls.
elevated in patients with renal failure without nephrotic syn-
drome or thrombosis [23, 24]. Accordingly, elevation of /3-
thromboglobulin levels is due to decreased renal elimination in
renal failure subsequently leading to accumulation. In most
previous studies elevated /3-thromboglobulin levels were de-
tected in patients with nephrotic syndrome and partially im-
paired renal function [7, 13, 14]. Thus it was not possible to
differentiate between the effects of impaired renal function
versus the effects of nephrotic syndrome. As all our patients
had a normal serum creatinine (creatinine clearance >70 mu
minll .73 m2) elevated /3-thromboglobulin levels in nephrotic
syndrome could not be ascribed to impaired renal elimination
but may reflect a state of platelet hyperaggregability. These
results are in accordance with earlier results of Canavese et al
[15]. However, we did not find a correlation of f3-thromboglob-
ulin levels to other parameters of platelet aggregability. As
opposed to our results Walter and coworkers [9] found normal
/3-thromboglobulin levels in patients with nephrotic syndrome
and serum creatinine levels below 1.4 mgldl.
Platelet factor 4 levels are known to be independent of renal
function and therefore would be a suitable marker for platelet
hyperaggregability in patients with renal impairment. Unfortu-
nately, platelet factor 4 levels in patients with nephrotic syn-
drome did not differ significantly from controls in our study. A
earlier study also failed to establish a platelet factor 4 elevation
in patients with nephrotic syndrome [13].
Platelets from patients with nephrotic syndrome have been
reported to be hyperaggregable to aggregating agents like ADP,
epinephrine, arachidonic acid, collagen or thrombin [3, 4, 8,
10—13]. However, in most of these studies [3, 4, 8, 12, 13]
platelet count in platelet rich plasma (PRP) was not adjusted to
a constant value to perform platelet aggregation tests. How-
ever, the aggregating response is known to depend on platelet
number [25]. Therefore a significant thrombocytosis in patients
with nephrotic syndrome compared with controls [1, 6, 9, 13]
may have influenced the results of platelet hyperaggregability.
Our data now confirm previous results of enhanced platelet
aggregability in adjusted platelet-rich plasma stimulated by
ADP, collagen [10, 11] and arachidonic acid [10].
Standardization of platelet aggregation studies was only
established in 1985 by Vickers and Thompson [26]. The esti-
mated concentration of an aggregating agent to cause half
maximum velocity of primary aggregation (EC50) was detected
by adding up to 10 different concentrations of stimulant. An
epidemiological study using this method revealed a high sensi-
tivity and a good reproducibility [27]. We confirmed that
platelets from patients with nephrotic syndrome are hyperag-
gregable to ADP and collagen using the EC50 method in
adjusted PRP as well as to arachidonic acid established by
measuring threshold concentrations in adjusted PRP. We also
found a significant spontaneous aggregation of nephrotic plate-
lets with a good inversed correlation to serum albumin which
coincides with earlier results [7, 9].
In a few studies platelet aggregability to epinephrine and ADP
[5, 121 and to arachidonic acid [5, 8] could be reversed by
correction of hypoalbuminemia. Therefore platelet hyperaggre-
gability seems to be closely associated with hypoalbuminemia.
Our data show a correlation between ADP-induced aggregabil-
ity and hypoalbuminemia as well as between spontaneous
platelet aggregation and hypoalbuminemia, which gives support
to this hypothesis. Because ADP-induced primary aggregation
is independent of cyclooxygenase enzyme [28], there has to be
an association between albumin concentration and ADP-in-
duced platelet aggregation which is not related to platelet
prostaglandin metabolism. However, mechanisms are not yet
known.
Arachidonic acid metabolism was extensively investigated by
Yoshida and Aoki in one patient with nephrotic syndrome [5].
Compared to platelets of a normal donor there was increased
platelet malondialdehyde formation in a suspension of washed
platelets after stimulation with collagen. This effect was revers-
ible by adding albumin in vitro. Enhanced malondialdehyde
formation was also found in six nephrotic children compared
with five children with nephrotic syndrome in remission after
stimulation with thrombin [11]. It was postulated that platelet
hyperaggregability in nephrotic syndrome is caused by elevated
arachidonic acid availability to the cyclooxygenase pathway
due to reduced binding of arachidonic acid to albumin [8, 10,
16]. Nevertheless we found thromboxane B2 formation un-
changed in platelet rich plasma after stimulation with collagen
which corresponds with earlier results [10]. This contradiction
may be explained by the different experimental conditions of
washed platelet suspension on one hand and platelet rich
plasma on the other hand.
Studying release of radioactivity from '4C-arachidonic acid-
labeled platelets Stuart, Gerard and White [29] found a de-
creased release of arachidonic acid in the presence of hypoal-
buminemia after stimulation with thrombin. However, as
hypoalbuminemia leads to an enhanced conversion of this
released arachidonic acid by cyclooxygenase the overall con-
version of 14C-arachidonic acid to thromboxane B2 remained
the same, thus not being dependent on albumin concentration.
The effect of varying albumin concentrations on the release of
radioactivity from thrombin-treated platelets prelabeled with
5H-arachidonic acid was also studied by Deykin, Russell and
Vaillancourt [30]. Only albumin concentrations between 0 and
1.0 mg/mI substantially influenced the release of arachidonic
acid and its conversion to cyclooxygenase products. This range
of albumin concentrations is about 1/50 of the "physiologic"
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range in patients with nephrotic syndrome and controls (10 to 50
mglml).
Further investigations demonstrated an increased thrombox-
ane B2 or malondialdehyde formation respectively only after
stimulation with arachidonic acid [10, 16]. This could be re-
versed by in vitro addition of albumin. As a fatty acid arachi-
donic acid is bound to albumin. Arachidonic acid used for
stimulating a platelet suspension is already bound to the extra-
cellular albumin depending on its concentration. Thus albumin
may reduce the effective stimulating concentration of arachi-
donic acid in a dose-related manner. We therefore believe that
the results of arachidonic acid induced platelet aggregation as
well as the resulting elevated thromboxane B2 formation in
hypoalbuminemia are most likely an in vitro phenomenon.
In contrast to the effect of hypoalbuminemia on platelet
aggregation in nephrotic syndrome the relations of hypercho-
lesterolemia or hyperfibrinogenemia to platelet hyperaggrega-
bility in nephrotic syndrome are poorly investigated. In our
study platelet aggregability measured by EC50 ADP correlated
with serum cholesterol levels. An earlier study has already
shown a significant correlation of spontaneous platelet aggre-
gation to serum cholesterol levels [91. However, we failed to
establish a significant correlation between spontaneous platelet
aggregation and serum cholesterol. Hypercholesterolemia is a
main symptom of the nephrotic syndrome. Shattil et al [31]
demonstrated that the acquisition of cholesterol by platelets in
vitro is associated with increased platelet sensitivity to aggre-
gating agents. Also enrichment with cholesterol leads to a
increased release of radioactivity in '4C-arachidonic acid la-
beled platelets from normal donors stimulated with thrombin
[32]. Cholesterol is supposed to interfere with diglyceride lipase
and phospholipase A2 by affecting membrane fluidity [33].
These enzymes are involved in the release of arachidonic acid
from platelet phospholipids [34].
Furthermore, we found a significant correlation between
plasma fibrinogen levels and platelet aggregability determined
by EC50 ADP and spontaneous platelet aggregation which has
not been investigated in earlier studies so far. Fibrinogen is
known to link aggregating platelets through binding to platelet
glycoprotein receptor lib/Illa. Within physiologic ranges fibrin-
ogen levels correlate to platelet aggregability in terms of EC50
ADP [35]. High fibrinogen levels are also associated with an
increased risk of coronary heart disease and stroke [36]. In
participants of the Northwick Park Heart Study [27] increasing
platelet aggregability measured by EC50 ADP was shown to
correlate with rising plasma fibrinogen concentrations. Our data
confirmed a similar correlation in patients with nephrotic syn-
drome between plasma fibrinogen levels and platelet hyperag-
gregability.
We do not know which of these in vitro parameters really
reflect the in vivo situation of platelet aggregability. According
to our data, pronounced platelet hyperaggregability seems to be
related to hypoalbuminemia as well as to hypercholesterolemia
and high plasma fibrinogen, indicating a multifactorial genesis
of platelet hyperaggregability in nephrotic syndrome. Our re-
sults point to a disturbance of platelet function which is very
likely not dependent on arachidonic acid metabolism. A recent
study [37] showed an enhanced ristocetin-induced platelet
aggregation in patients with nephrotic syndrome which was not
investigated by us. There was no relation between ristocetin-
induced platelet aggregation and hypoalbuminemia or platelet
arachidonic acid metabolism. However, the effect of serum
cholesterol levels and plasma fibrinogen levels has not been
reported. We conclude that thrombotic risk in patients with
nephrotic syndrome may not to be treated with inhibitors of
platelet cyclooxygenase.
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